))
The World in a Grain of Sand: Verve Therapeutics
Manage episode 402270909 series 3526488
内容由KdT Ventures提供。所有播客内容（包括剧集、图形和播客描述）均由 KdT Ventures 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品，您可以按照此处概述的流程进行操作https://zh.player.fm/legal。
KdT Ventures presents The World in a Grain of Sand, where we break down an S1 from a recent biotech IPO and share insights on the science, business models, and financials. In this episode, Ketan Yerneni and Mack Healy discuss Verve Therapeutics, a gene editing biotech tackling one of the most common chronic diseases: cardiovascular disease. We dive into:
- Base editing, and its advantages over traditional (potentially error-prone) CRISPR.
- Verve’s pipeline, including their strategy of starting with genetically well-defined diseases like familial hypercholesterolemia and then expanding to the general population of patients with atherosclerotic cardiovascular disease.
- Verve’s approach for predicting off-target gene editing, a key challenge for the gene editing field.
- Verve’s unique licensing strategy with Beam, Acuitas, and the Broad to secure several foundational technologies.
- The competitive landscape and target product profile tradeoffs for one-and-done gene editing approaches vs other therapeutic modalities.
- and more.
For updates from KdT, subscribe to our Substack.
13集单集
分享
